MARBURG

Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa

Retrieved on: 
Thursday, April 25, 2024
Ricin, Vaccination, University, Small business, Pandemic, Freeze-drying, NIH, Tropical medicine, Public health, Doctor of Philosophy, Associate professor, Vaccine, Particle size, Senior, University of Hawaiʻi, Patent, Element, Antigen, Temperature, Immunity, COVID-19, Infection

The Company has previously announced multiple issued patents within the same patent family in the United States (U.S.).

Key Points: 
  • The Company has previously announced multiple issued patents within the same patent family in the United States (U.S.).
  • "Elements of this vaccine platform have been utilized in our ricin toxin, filovirus and COVID-19 vaccine candidates, indicating its broad applicability.
  • We continue to focus on vaccine development against Sudan ebolavirus and Marburg marburgvirus where there are currently no available vaccines."
  • The thermostabilized filovirus vaccine program has been supported by a National Institute of Health (NIH) grant R01-AI132323 (awarded to the University of Hawaii) and a Small Business Innovation Research grant (#1R44AI157593-01; awarded to Soligenix).

Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Marburg Vaccine in Uganda

Retrieved on: 
Thursday, October 19, 2023
Biomedical Advanced Research and Development Authority, Guinea, Makerere University Walter Reed Project, Sabin Vaccine Institute, Vaccine, Family, Human services, Kenya Medical Research Institute, Administration for Strategic Preparedness and Response, Viral hemorrhagic fever, Organization, BARDA, United States Department of Health and Human Services, Research, Volunteering, Administration, Development, Epidemic, Disease, Clinical trial, Blood, Safety, Office of Inspector General, U.S. Department of Health and Human Services, Polio, Marburg virus disease, Medical device, Pharmaceutical industry

WASHINGTON, Oct. 19, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute has launched a Phase 2 clinical trial for its vaccine candidate against the lethal Marburg virus. Healthy volunteers received the single-dose vaccine at Makerere University Walter Reed Project (MUWRP) in Kampala, Uganda today.

Key Points: 
  • WASHINGTON, Oct. 19, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute has launched a Phase 2 clinical trial for its vaccine candidate against the lethal Marburg virus.
  • “Makerere University Walter Reed Project (MUWRP) is delighted to partner with the Sabin Vaccine Institute to launch the clinical testing for a preventive Marburg vaccine,” says Dr. Mwesigwa.
  • In addition to the current trial in Uganda and Kenya, Sabin plans to conduct a similar Phase 2 clinical trial for Marburg in the U.S.
  • Sabin has also initiated plans for a Phase 2 Sudan ebolavirus vaccine clinical trial in Uganda and Kenya.

Soligenix Announces Achievement of Two-Year Stability with Bivalent and Trivalent Thermostabilized Filovirus Vaccines when Stored at High Temperatures

Retrieved on: 
Monday, September 25, 2023
Vaccine, Antigen, University of Colorado School of Medicine, John A. Burns School of Medicine, University, Senior, Vaccination, Associate professor, COVID-19, UHM, Immunity, Temperature, Doctor of Philosophy, Bangladesh Technical Education Board, Biology, Foundation for the National Institutes of Health, Ricin, Administration, Public health, Primate, Tropical medicine, Small business, Theodore Fitz Randolph, Particle size, NIH, Element, Pharmacology

This follows the previous successful demonstration of 100% protection of non-human primates (NHPs) against lethal Sudan ebolavirus and Marburg marburgvirus challenge with the bivalent vaccine.

Key Points: 
  • This follows the previous successful demonstration of 100% protection of non-human primates (NHPs) against lethal Sudan ebolavirus and Marburg marburgvirus challenge with the bivalent vaccine.
  • It further demonstrates the broad applicability of the heat stable vaccine platform, and its potential role in the United States (U.S.) Administration's initiative for pandemic preparedness .
  • There are no licensed vaccines for either Sudan or Marburg viruses, while vaccines for Zaire ebolavirus are constrained by cold chain logistics.
  • This most recent milestone confirms the robust thermostabilization provided by this vaccine platform.

EQS-News: RHÖN-KLINIKUM AG looks back on successful Q1 2023

Retrieved on: 
Thursday, May 11, 2023
News, Partnership, Bed, Health in the Federated States of Micronesia, Teaching, COVID-19, University, Tax, Asclepius, Research, Person, EBITDA, Patient, Giessen, Nursing, Assessment, Depreciation, Federalism, Health, Adjustment, Security (finance), Hospital

RHÖN-KLINIKUM AG, one of the largest healthcare providers in Germany, has made a good start into the new financial year.

Key Points: 
  • RHÖN-KLINIKUM AG, one of the largest healthcare providers in Germany, has made a good start into the new financial year.
  • In the first three months of financial year 2023, the Group of RHÖN-KLINIKUM AG recorded revenues of 361.5 million euros after 347.3 million euros in the same period of the previous year.
  • From January to March we treated 228,189 patients, 6.5 per cent more than in the same period last year (previous year Q1 2022: 214,321).
  • www.rhoen-klinikum-ag.com
    RHÖN-KLINIKUM AG | Schlossplatz 1 | D-97616 Bad Neustadt a. d. Saale
    11.05.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.

Veru Announces Preclinical Study Results that Demonstrate Sabizabulin Inhibits Poxviruses

Retrieved on: 
Tuesday, April 11, 2023
Microtubule, Infection, University of Rochester Medical Center, Human, Partnership, University, EEV, Marketing, Public, Mpox, COVID-19, African, Animal efficacy rule, CFR, Smallpox, Research, Cmax, Cavg, Associate, Development, Patient, Multiple organ dysfunction syndrome, Dentistry, Immunology, Viral, FDA, Death, BARDA, Virus, Pneumonia, Vaccine, Microbiology, Vaccinia

MIAMI, FL, April 11, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced results from a preclinical in vitro study evaluating the effects of sabizabulin against prototypical poxvirus, vaccinia virus, which demonstrated that sabizabulin prevented both the release of poxvirus from infected cells and the spread of poxvirus to healthy cells. These preclinical study results support the expansion of sabizabulin’s program into additional indications to potentially treat the lethal smallpox virus infection or other related infections if a worldwide emergency outbreak occurs.

Key Points: 
  • These preclinical study results support the expansion of sabizabulin’s program into additional indications to potentially treat the lethal smallpox virus infection or other related infections if a worldwide emergency outbreak occurs.
  • The purpose of the study was to evaluate the mechanism of antiviral efficacy of sabizabulin, a novel microtubule disruptor, against the prototypical poxvirus vaccinia in cell culture.
  • To assess the ability of sabizabulin to slow or stop vaccinia virus cell-to-cell spread, BSC40 cells were treated with different concentrations of sabizabulin before inoculation with vaccinia virus at a low multiplicity of infection.
  • In this study, sabizabulin, by disrupting microtubules, was able to prevent the export and release of infectious vaccinia virus.

Sabin Vaccine Institute Receives $35 Million from BARDA with Potential of up to $214 Million for Ebola Sudan and Marburg Vaccines

Retrieved on: 
Thursday, January 12, 2023
Biomedical Advanced Research and Development Authority, Office of Inspector General, U.S. Department of Health and Human Services, Finan of Lindisfarne, World Health Organization, Development, Fever, U.S. Department of Commerce Office of Security, Administration, Ebola, Human services, Vaccine, Sabin Vaccine Institute, Partnership, Death, BARDA, ASPR, United States Department of Health and Human Services

There are currently no licensed vaccines against Ebola Sudan and Marburg viruses, which cause hemorrhagic fever and kill approximately half the people infected.

Key Points: 
  • There are currently no licensed vaccines against Ebola Sudan and Marburg viruses, which cause hemorrhagic fever and kill approximately half the people infected.
  • These vaccines may be used as part of ongoing U.S. preparedness efforts and in response to future global outbreaks.
  • The country declared the Ebola Sudan outbreak had ended on January 11 , four months after the first confirmed case.
  • “Sabin successfully delivered Ebola Sudan vaccine doses to Uganda within 79 days of the start of the outbreak – quite an impressive accomplishment,” says Sabin Chief Executive Officer Amy Finan.

Sabin Receives Additional $21.8 Million From BARDA to Advance Marburg Vaccine

Retrieved on: 
Wednesday, September 14, 2022
Disability, Safety, Development, Biomedical Advanced Research and Development Authority, Human, Department, Sabin, Policy, Twitter, Office of Inspector General, U.S. Department of Health and Human Services, Virus, United States Department of Health and Human Services, BARDA, Administration, Sabin Vaccine Institute, Partnership, U.S. Department of Defense Strategy for Operating in Cyberspace, Primate, Viral hemorrhagic fever, Human services, Vaccine, Solution, DRC, Marburg virus disease, Ecosystem, Research, GLOBE, Animal, Ebola River, Disease, Death

The Sabin Marburg vaccine is the only candidate currently slated for a Phase 2 clinical trial.

Key Points: 
  • The Sabin Marburg vaccine is the only candidate currently slated for a Phase 2 clinical trial.
  • The latest tranche of funds enables Sabin to conduct a randomized, blinded, placebo-controlled clinical trial among adults in the U.S. to further evaluate the safety and the efficacy of the Marburg vaccine candidate and advance non-clinical vaccine dosing studies.
  • In 2019, BARDA awarded Sabin a multi-year contract valued at $128 million to further the development of vaccines against two lethal viruses: Marburg and Ebola Sudan.
  • The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation.

CSL presents new research and development center in Marburg, Germany

Retrieved on: 
Tuesday, September 13, 2022
CSL, Plasma, ASX, United Nations Sustainable Development Group, Sustainable Development Goal 9, KfW, Carbon, Development, Haemophilia, Recycling, M600, A-DNA, Research, Canadian industrial research and development organizations, Nobel Prize, Goal, CSL Behring, Perreault, Growth, Calendar, Patient, Immunodeficiency, Natural Resources, Cell, Vaccine, Science, Ecosystem, Gene therapy, Biotechnology, R, Diphtheria, CSL Limited, Fine chemical, Renewable energy, Medicine

MARBURG, Germany, Sept. 13, 2022 /PRNewswire/ -- After three years of construction, global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY), today, inaugurated its new EUR 150 million research and development (R&D) site on the grounds of the research campus in Marburg's Görzhausen Industrial Park. Covering around 40,000 square meters, the M600 R&D center provides space for up to 500 R&D employees, making it CSL's largest R&D center worldwide and combining all disciplines under one roof. 

Key Points: 
  • MARBURG, Germany, Sept. 13, 2022 /PRNewswire/ -- After three years of construction, global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY), today, inaugurated its new EUR 150 million research and development (R&D) site on the grounds of the research campus in Marburg's Grzhausen Industrial Park.
  • Construction of CSL's new M600 research and development (R&D) center in Marburg, Germany, began in November 2019 and will be completed later this calendar year.
  • It will also provide space for around 500 CSL research and development employees as well as academic and cooperation partners.
  • Today, CSL including our three businesses, CSL Behring, CSL Seqirus, and CSL Vifor provides lifesaving products to patients in more than 100 countries and employs more than 30,000 people.

BioCryst to Report Fourth Quarter 2021 Financial Results on February 23

Retrieved on: 
Wednesday, February 9, 2022
GLOBE, BioCryst Pharmaceuticals, RESEARCH, Yellow fever, Marburg virus disease, Union, ID, PARK, United Arab Emirates, United Kingdom, Nasdaq, Disease, Webcast, Galidesivir, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., Feb. 09, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter and full year 2021 financial results Wednesday, February 23, 2022.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Feb. 09, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter and full year 2021 financial results Wednesday, February 23, 2022.
  • BioCryst management will host a conference call and webcast at 8:30 a.m.
  • ET that day to discuss the financial results and provide a corporate update.
  • The live call may be accessed by dialing 877-303-8027 for domestic callers and 760-536-5165 for international callers and using conference ID # 6365545.

GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference

Retrieved on: 
Tuesday, February 8, 2022
GLOBE, Form, Head, Patent, Conference, Zika virus, Research, Company, Malaria, Cancer, Infection, FDA, Patient, SEC, Immunotherapy, Human, CEO, Risk, BIO, GeoVax, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Nasdaq, Vaccine, Food, Immunodeficiency, COVID-19, Pharmaceutical industry, Security (finance)

Atlanta, GA, Feb. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that its Chairman and CEO, David Dodd, will present a company overview at the 2022 BIO CEO & Investor Digital Conference taking place February 14-17, 2022.

Key Points: 
  • Atlanta, GA, Feb. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that its Chairman and CEO, David Dodd, will present a company overview at the 2022 BIO CEO & Investor Digital Conference taking place February 14-17, 2022.
  • The Company is currently scheduling meetings with institutional investors during the conference.
  • Parties interested in scheduling meetings with GeoVaxs senior management team may register for the conference at https://www.bio.org/events/bio-ceo-investor-conference/investor-registra... .
  • GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer using novel proprietary platforms.